MaxCyte inks research agreement with Gilead subsidiary Kite Pharma
The AIM-listed bioscience firm said under the agreement Kite would use its Flow Electroporation Technology platform to enable non-viral cell engineering
Company
Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc is a biopharmaceutical company. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. Gilead Sciences Inc offers products in HIV, Onocolgy, Liver Disease, Vekulaery and Other.
86 stories · page 3 of 5
A sixth sense for biotech helps Arix Bioscience turn risk into profit as portfolio value nearly doubles
Analysts at Stifel say the venture capital firm is entering its first extended period of sustained news flow with shares trading at about 45% discount to their £2.53 price target
EARLY MOVERS: Apple set to create big buzz as it reveals new iPhones; Micron Technology shares down after Goldman note
Also in focus in pre-market deals is Bausch Health Cos Inc, formerly Valeant, and Gilead Sciences
Large-cap biotech companies seem poised to outperform in 2Q, says Oppenheimer analyst
'We remain cautiously bullish on the sector, albeit with a stock-picking approach,' writes Hartaj Singh
Gilead Sciences’s 1Q earnings miss gets shares, but Oppenheimer analysts say not to worry
Sales of the California biotech's cancer drug Yescarta was double what analysts expected
Gilead Sciences misses on 1Q earnings and revenue, maintains outlook
The biopharma company recently announced a partnership with Alphabet start-up Verily Life Science
Gilead Sciences strikes partnership with Alphabet's Verily
Forbes reported Gilead would pay Verily US$90mln to probe immune cells
Gilead Sciences and Sangamo Therapeutics to collaborate on engineered cell therapies for cancer treatment
Kite will use Sangamo's zine finger nuclease technology platform to develop the next-generation therapies for autologous and allogeneic use in treating different cancers
GlaxoSmithKline winning over City number crunchers
Is the market being too negative about the prospects for the HIV franchise and generic competition to its best-selling asthma treatment, Advair?
Abzena a play on the biologics revolution, says City broker
The subsector in which Abezena is active in (monoclonal antibody and conjugated monoclonal antibodies) could expand to US$180bn, Peel Hunt’s research suggests
GSK sues US rival Gilead Sciences for alleged HIV drug patent infringement
GSK’s one pill, once daily treatment was approved back in November, while Gilead’s drug got the green light from the US FDA on Wednesday
GSK warns 2018 earnings hinge on generic competition to its blockbuster Advair inhaler
If a generic competitor comes to market this summer as expected, GSK said earnings will fall by between 0-3%, while if a competitor isn’t forthcoming, earnings will rise by 4-7%
Snap, Gilead Sciences, Walt Disney Co and more - AFTER HOURS
Proactive takes a look t what happened after the bell in New York
Gilead Sciences, Celgene Corp, Cytokinetics and more - PRE-MARKET
Proactive takes a look at what's piquing investor interest before the bell in New York
GSK steals a march on rivals as its two drug, one pill HIV treatment gets green light from FDA
Juluca – as the treatment is known – is made by GSK’s majority-controlled ViiV Healthcare and is the first such drug to be approved by US authorities
Gilead Sciences shares bolstered after FDA approval validates Kite Pharma merger
This is a huge win for the pharma group, and validates its US$12bn acquisition this summer of Kite Pharma Inc
Verizon Communications, Gilead Sciences, Alcoa Corp, PayPal Holdings - PRE-MARKET
We take a look at what's moving the needle in New York, ahead of the bell
Wall Street shares mixed going into close
US shares started Monday mixed after futures had pointed lower
United Therapeutics opens 10% higher as GlaxoSmithKline is named as a potential bidder for the group
Sources are cited as saying the bidding could go as high as US$200 a share, valuing the business at US$8.7bn
Facebook, Gilead Sciences and Discover Financial Services and more
We are looking at all the movers and shakers after the bell